218 related articles for article (PubMed ID: 30209057)
1. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study.
Pottegård A; Kristensen KB; Ernst MT; Johansen NB; Quartarolo P; Hallas J
BMJ; 2018 Sep; 362():k3851. PubMed ID: 30209057
[TBL] [Abstract][Full Text] [Related]
2.
Mansouri I; Botton J; Semenzato L; Haddy N; Zureik M
J Am Heart Assoc; 2022 Dec; 11(24):e8067. PubMed ID: 36533625
[TBL] [Abstract][Full Text] [Related]
3. N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer—A Longitudinal Cohort Study Based on German Health Insurance Data.
Gomm W; Röthlein C; Schüssel K; Brückner G; Schröder H; Heß S; Frötschl R; Broich K; Haenisch B
Dtsch Arztebl Int; 2021 May; 118(21):357-362. PubMed ID: 34247699
[TBL] [Abstract][Full Text] [Related]
4. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products.
Snodin DJ; Elder DP
Regul Toxicol Pharmacol; 2019 Apr; 103():325-329. PubMed ID: 30629969
[TBL] [Abstract][Full Text] [Related]
5. Analysis of an Impurity, N-Nitrosodimethylamine, in Valsartan Drug Substances and Associated Products Using GC-MS.
Tsutsumi T; Akiyama H; Demizu Y; Uchiyama N; Masada S; Tsuji G; Arai R; Abe Y; Hakamatsuka T; Izutsu KI; Goda Y; Okuda H
Biol Pharm Bull; 2019 Apr; 42(4):547-551. PubMed ID: 30726781
[TBL] [Abstract][Full Text] [Related]
6. Association between ranitidine use with potential NDMA impurities and risk of cancer in Korea.
Joung KI; Hwang JE; Oh IS; Cho SI; Shin JY
Sci Rep; 2022 Dec; 12(1):22396. PubMed ID: 36575247
[TBL] [Abstract][Full Text] [Related]
7. NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines.
Parr MK; Joseph JF
J Pharm Biomed Anal; 2019 Feb; 164():536-549. PubMed ID: 30458387
[TBL] [Abstract][Full Text] [Related]
8. Rapid and efficient high-performance liquid chromatography analysis of N-nitrosodimethylamine impurity in valsartan drug substance and its products.
Masada S; Tsuji G; Arai R; Uchiyama N; Demizu Y; Tsutsumi T; Abe Y; Akiyama H; Hakamatsuka T; Izutsu KI; Goda Y; Okuda H
Sci Rep; 2019 Aug; 9(1):11852. PubMed ID: 31413326
[TBL] [Abstract][Full Text] [Related]
9. Understanding and Preventing (
White CM
Ann Pharmacother; 2020 Jun; 54(6):611-614. PubMed ID: 31771343
[No Abstract] [Full Text] [Related]
10. Abrupt Increase in Reporting of Neoplasms Associated with Valsartan After Medication Recall.
Al-Kindi SG; Oliveira GH
Circ Cardiovasc Qual Outcomes; 2019 Jul; 12(7):e005536. PubMed ID: 31266370
[No Abstract] [Full Text] [Related]
11. Cancer risk associated with the use of valsartan in Korea: A nationwide cohort study.
Jeon HL; Lee SH; Nam JH; Shin JY
Cancer Epidemiol; 2022 Oct; 80():102245. PubMed ID: 36087359
[TBL] [Abstract][Full Text] [Related]
12. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.
Iversen L; Fielding S; Lidegaard Ø; Mørch LS; Skovlund CW; Hannaford PC
BMJ; 2018 Sep; 362():k3609. PubMed ID: 30257920
[TBL] [Abstract][Full Text] [Related]
13. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
Charoo NA; Ali AA; Buha SK; Rahman Z
AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
[TBL] [Abstract][Full Text] [Related]
14. Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40.
Engels EA; Katki HA; Nielsen NM; Winther JF; Hjalgrim H; Gjerris F; Rosenberg PS; Frisch M
J Natl Cancer Inst; 2003 Apr; 95(7):532-9. PubMed ID: 12671021
[TBL] [Abstract][Full Text] [Related]
15. Pharmacists are key in interpreting clinical implications of N-nitrosodimethylamine contamination in medications.
Eads AV
J Am Pharm Assoc (2003); 2020; 60(6):e100-e104. PubMed ID: 32741598
[TBL] [Abstract][Full Text] [Related]
16. Risk of Cancer Following the Use of N-Nitrosodimethylamine (NDMA) Contaminated Ranitidine Products: A Nationwide Cohort Study in South Korea.
Yoon HJ; Kim JH; Seo GH; Park H
J Clin Med; 2021 Jan; 10(1):. PubMed ID: 33466237
[TBL] [Abstract][Full Text] [Related]
17. The contamination of valsartan and other sartans, part 1: New findings.
Sörgel F; Kinzig M; Abdel-Tawab M; Bidmon C; Schreiber A; Ermel S; Wohlfart J; Besa A; Scherf-Clavel O; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():395-405. PubMed ID: 31122801
[TBL] [Abstract][Full Text] [Related]
18. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.
Nyboe Andersen N; Pasternak B; Basit S; Andersson M; Svanström H; Caspersen S; Munkholm P; Hviid A; Jess T
JAMA; 2014 Jun; 311(23):2406-13. PubMed ID: 24938563
[TBL] [Abstract][Full Text] [Related]
19. Implantable cardioverter-defibrillators and subsequent cancer risk: a nationwide population-based cohort study.
Pedersen SB; Nielsen JC; Bøtker HE; Farkas DK; Schmidt M; Sørensen HT
Europace; 2015 Jun; 17(6):902-8. PubMed ID: 25840286
[TBL] [Abstract][Full Text] [Related]
20. Dietary N-nitroso compounds and risk of colorectal cancer: a case-control study in Newfoundland and Labrador and Ontario, Canada.
Zhu Y; Wang PP; Zhao J; Green R; Sun Z; Roebothan B; Squires J; Buehler S; Dicks E; Zhao J; Cotterchio M; Campbell PT; Jain M; Parfrey PS; Mclaughlin JR
Br J Nutr; 2014 Mar; 111(6):1109-17. PubMed ID: 24160559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
